On 12 September 2024, Sanofi and Regeneron announced that Health Canada has approved Dupixent® (dupilumab) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). This approval expands the initial Health Canada approval for EoE in May 2023 for patients aged 12 years and older, weighing at least 40 kg.
Dupixent® has previously received FDA approval for these indications, being approved for paediatric patients aged 1 to 11 years (weighing at least 15 kg) with EOE in January 2024 and for EoE in patients 12 years and older in May 2022.